undamentalytics Newsletter
Sign in

Regeneron Pharmaceuticals dividend history

Regeneron Pharmaceuticals paid $370m in dividends in fiscal 2025. That was 8.2% of net income.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$3B
Dividends (TTM)
$383M
Returned to shareholders
89%
of free cash flow
Buybacks, last 3 fiscal years
$8.3B
Diluted share count
−3.2%
year over year
Total shareholder yield
3.4%
dividends 0.4% + buybacks 3.0% of market value
Dividend payout ratio
8%
of net income paid out
R&D spending
39.0%
of revenue
Sales & admin spending
16.4%
of revenue
Days sales outstanding
164 days
receivables vs revenue

Dividends by fiscal year

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Dividends paid——————————————00370383
Share buybacks———————0042765,8471,6452,0832,2352,6033,4393,035
Dividends ÷ net income——————————————0.0%0.0%8.2%8.0%
Dividends ÷ free cash flow——————————————0.0%0.0%9.1%10.0%

Dividend per share is the amount declared for the fiscal year as stated in the company's filings (including any special dividend), restated for stock splits and checked against the cash dividends paid. Dividends paid and buybacks are cash amounts; the last-twelve-months column can include an extra payment when a quarter-end date moves.

Compare with peers

Head to head: GILD vs REGNAMGN vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regeneron Pharmaceuticals.